­
­

Pipeline

Rigorous and groundbreaking science has always been at the core of what we do at Genentech. Our R&D activities are focused on applying excellent science to discover and develop potential new medicines with the goal of becoming first-in-class or best-in-class therapeutics.

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

Anti-latent TGF-beta1 (SOF10)
Solid tumors
Solid tumors
Oncology
Phase 1
AR degrader
Metastatic castration-resistant prostate cancer (mCRPC)
Metastatic castration-resistant prostate cancer (mCRPC)
Oncology
Phase 1
Astegolimab
Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Immunology
Phase 3
Atezolizumab
Solid tumors
Solid tumors
Oncology
Phase 1
Atezolizumab
Previously untreated metastatic triple negative breast cancer (IMpassion132)
Previously untreated metastatic triple negative breast cancer (IMpassion132)
Oncology
Phase 3
Atezolizumab
Neoadjuvant triple negative breast cancer (IMpassion031)
Neoadjuvant triple negative breast cancer (IMpassion031)
Oncology
Phase 3
Atezolizumab
Adjuvant triple negative breast cancer (IMpassion030)
Adjuvant triple negative breast cancer (IMpassion030)
Oncology
Phase 3
Autogene cevumeran
Solid tumors
Solid tumors
Oncology
Phase 1
Autogene cevumeran
Advanced melanoma
Advanced melanoma
Oncology
Phase 2
Autogene cevumeran
Adjuvant pancreatic ductal adenocarcinoma (PDAC)
Adjuvant pancreatic ductal adenocarcinoma (PDAC)
Oncology
Phase 2
Baloxavir marboxil
Influenza in children ages 1 and older
Influenza in children ages 1 and older
Infectious Disease
Phase 3
Baloxavir marboxil
Reduction of transmission of influenza in households
Reduction of transmission of influenza in households
Infectious Disease
Phase 3
Cevostamab
Relapsed or refractory multiple myeloma
Relapsed or refractory multiple myeloma
Oncology
Phase 1
Cobimetinib
Metastatic melanoma
Metastatic melanoma
Oncology
Phase 3
Crovalimab
Paroxysmal nocturnal hemoglobinuria (PNH)
Paroxysmal nocturnal hemoglobinuria (PNH)
Other
Phase 3
Delandistrogene Moxeparvovec (SRP-9001)
Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Neuroscience
Phase 3
Emicizumab
Hemophilia A
Hemophilia A
Other
Phase 3
Englumafusp alfa (RG6076)
Heme tumors
Heme tumors
Oncology
Phase 1
Entrectinib
Solid Tumors
Solid Tumors
Oncology
Phase 2
Entrectinib
Non-small cell lung cancer
Non-small cell lung cancer
Oncology
Phase 2
Fenebrutinib
Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Neuroscience
Phase 3
Fenebrutinib
Primary Progressive Multiple Sclerosis
Primary Progressive Multiple Sclerosis
Neuroscience
Phase 3
Gazyva
Systemic lupus erythematosus
Systemic lupus erythematosus
Immunology
Phase 3
Giredestrant
Grade 1 endometrioid endometrial cancer
Grade 1 endometrioid endometrial cancer
Oncology
Phase 2
Giredestrant
ER+ HER2-negative breast cancer, adjuvant ER+ breast cancer
ER+ HER2-negative breast cancer, adjuvant ER+ breast cancer
Oncology
Phase 3
Giredestrant
1L ER+ metatstatic breast cancer
1L ER+ metatstatic breast cancer
Oncology
Phase 3
Glofitamab
Heme tumors
Heme tumors
Oncology
Phase 1
Glofitamab
R/R mantle cell lymphoma
R/R mantle cell lymphoma
Oncology
Phase 3
Glofitamab
1L diffuse large B-cell lymphoma
1L diffuse large B-cell lymphoma
Oncology
Phase 3
Glofitamab
2L+ diffuse large B-cell lymphoma
2L+ diffuse large B-cell lymphoma
Oncology
Phase 3
Inavolisib (GDC-0077)
HR+, HER2-negative, PIK3CA mutated mBC post CDK4/6i therapy (INAVO121)
HR+, HER2-negative, PIK3CA mutated mBC post CDK4/6i therapy (INAVO121)
Oncology
Phase 3
Inavolisib (GDC-0077)
Solid tumors and ER+ HER2-negative breast cancer
Solid tumors and ER+ HER2-negative breast cancer
Oncology
Phase 1
Inavolisib (GDC-0077)
PIK3CA-mutant HR+ mBC in combination with palbociclib fulvestrant
PIK3CA-mutant HR+ mBC in combination with palbociclib fulvestrant
Oncology
Phase 3
IONIS-FB-LRx
Geographic Atrophy (GA)
Geographic Atrophy (GA)
Ophthalmology
Phase 2
KRAS G12C (GDC-6036)
Metastatic solid tumors with KRAS G12C mutation
Metastatic solid tumors with KRAS G12C mutation
Oncology
Phase 1
Mosunetuzumab
Heme tumors
Heme tumors
Oncology
Phase 1
Mosunetuzumab
2L+ follicular lymphoma
2L+ follicular lymphoma
Oncology
Phase 3
Mosunetuzumab
2L+ diffuse large B-cell lymphoma
2L+ diffuse large B-cell lymphoma
Oncology
Phase 3
Mosunetuzumab
Systemic lupus erythematosus
Systemic lupus erythematosus
Immunology
Phase 1
Obinutuzumab
Systemic lupus erythematosus
Systemic lupus erythematosus
Immunology
Phase 3
Obinutuzumab
Lupus nephritis
Lupus nephritis
Immunology
Phase 3
Omalizumab
Food Allergies
Food Allergies
Immunology
Phase 3
Pertuzumab
Early HER2-positive breast cancer in combination with trastuzumab emtansine
Early HER2-positive breast cancer in combination with trastuzumab emtansine
Oncology
Phase 3
Pertuzumab
Early and metastatic HER2-positive breast cancer in combination with atezolizumab
Early and metastatic HER2-positive breast cancer in combination with atezolizumab
Oncology
Phase 1
Port Delivery System with ranibizumab
Diabetic Macular Edema (DME)
Diabetic Macular Edema (DME)
Ophthalmology
Phase 3
Port Delivery System with ranibizumab
Diabetic Retinopathy without DME
Diabetic Retinopathy without DME
Ophthalmology
Phase 3
Prasinezumab
Parkinson’s disease
Parkinson’s disease
Neuroscience
Phase 2
RG6035 BrainShuttleTM CD20
Multiple Sclerosis
Multiple Sclerosis
Neuroscience
Phase 1
RG6120 (VEGF-Ang2 DutaFab)
wet age-related macular degeneration (AMD)
wet age-related macular degeneration (AMD)
Ophthalmology
Phase 1
RG6163
Psychiatric disorders
Psychiatric disorders
Neuroscience
Phase 1
RG6179
Diabetic Macular Edema (DME)
Diabetic Macular Edema (DME)
Ophthalmology
Phase 2
RG6179
Uveitic Macular Edema (UME)
Uveitic Macular Edema (UME)
Ophthalmology
Phase 3
RG6182
Neurodegenerative diseases
Neurodegenerative diseases
Neuroscience
Phase 1
RG6237
Neuromuscular disorders
Neuromuscular disorders
Neuroscience
Phase 1
RG6287
Acute graft versus host disease (aGVHD)
Acute graft versus host disease (aGVHD)
Immunology
Phase 1
RG6289
Alzheimer's Disease
Alzheimer's Disease
Neuroscience
Phase 1
RG6315
Immunologic Disorders
Immunologic Disorders
Immunology
Phase 1
RG6351
Retinal Disease
Retinal Disease
Ophthalmology
Phase 1
RG6411
Solid tumors
Solid tumors
Oncology
Phase 1
RG6421
Muco-obstructive respiratory disease
Muco-obstructive respiratory disease
Immunology
Phase 1
RG6436
Complicated urinary tract infection
Complicated urinary tract infection
Infectious Disease
Phase 1
RG6468
Solid tumors
Solid tumors
Oncology
Phase 1
RG6501 (OpRegen)
Geographic Atrophy (GA)
Geographic Atrophy (GA)
Ophthalmology
Phase 2
RG6536 (Vixarelimab)
Idiopathic pulmonary fibrosis / Systemic sclerosis-associated interstitial lung disease (IPF & SSc-ILD)
Idiopathic pulmonary fibrosis / Systemic sclerosis-associated interstitial lung disease (IPF & SSc-ILD)
Immunology
Phase 2
RG6538
Heme tumors
Heme tumors
Oncology
Phase 1
RG6540
Heme tumors
Heme tumors
Oncology
Phase 1
RG6561
Solid tumors
Solid tumors
Oncology
Phase 1
RG6620
Solid tumors with KRAS G12D mutations
Solid tumors with KRAS G12D mutations
Oncology
Phase 1
RG7774
Diabetic Retinopathy
Diabetic Retinopathy
Ophthalmology
Phase 2
RG7921
wet age-related macular degeneration (AMD)
wet age-related macular degeneration (AMD)
Ophthalmology
Phase 1
rhPentraxin-2
Myelofibrosis
Myelofibrosis
Infectious Disease
Phase 2
tenecteplase
acute ischemic stroke (AIS)
acute ischemic stroke (AIS)
Neuroscience
Phase 3
Tiragolumab
Non-small cell lung cancer
Non-small cell lung cancer
Oncology
Phase 3
Tiragolumab
Esophageal cancer
Esophageal cancer
Oncology
Phase 3
Tiragolumab
Squamous cell carcinoma of head and neck
Squamous cell carcinoma of head and neck
Oncology
Phase 2
Tominersen
Early / Prodromal Huntington’s disease
Early / Prodromal Huntington’s disease
Neuroscience
Phase 2
Trastuzumab emtansine
1st line HER2-positive metastatic breast cancer
1st line HER2-positive metastatic breast cancer
Oncology
Phase 3
Trastuzumab emtansine
Early HER2-positive breast cancer in combination with pertuzumab
Early HER2-positive breast cancer in combination with pertuzumab
Oncology
Phase 3
Trastuzumab emtansine
Early and metastatic HER2-positive breast cancer in combination with atezolizumab
Early and metastatic HER2-positive breast cancer in combination with atezolizumab
Oncology
Phase 3
Trastuzumab emtansine
3rd line HER2-positive metastatic breast cancer
3rd line HER2-positive metastatic breast cancer
Oncology
Phase 3
Trastuzumab emtansine
2L + HER-2+ PD-L1+ mBC (KATE3)
2L + HER-2+ PD-L1+ mBC (KATE3)
Oncology
Phase 3
Trastuzumab emtansine
HER2-positive early breast cancer high-risk patients (ASTEFANIA)
HER2-positive early breast cancer high-risk patients (ASTEFANIA)
Oncology
Phase 3
trontinemab
Alzheimer’s disease
Alzheimer’s disease
Neuroscience
Phase 2
Vemurafenib
Papillary thyroid cancer, BRAF mutation positive
Papillary thyroid cancer, BRAF mutation positive
Oncology
Phase 2
Venetoclax
1L chronic lymphocytic leukemia
1L chronic lymphocytic leukemia
Oncology
Phase 3
Venetoclax
1L myelodysplastic syndromes
1L myelodysplastic syndromes
Oncology
Phase 3
Vismodegib
Operable basal cell carcinoma
Operable basal cell carcinoma
Oncology
Phase 2